|
Age, yrs
|
33.6 ± 1.9
|
34.9 ± 1.9
|
34.3 ± 1.3
|
|
Gender, (M:F)
|
9:11
|
6:14
|
15:25
|
|
BMI, (kg/m2)
|
20.6 ± 0.6
|
20.5 ± 0.7
|
20.5 ± 0.4
|
|
GERD symptom score (frequency x severity)*
|
22.0 ± 3.2
|
30.5 ± 4.6
|
26.2 ± 2.9
|
|
DeMeester score*
|
5.3 ± 0.9
|
44.2 ± 7.1
|
24.8 ± 4.7
|
|
Asthma severity* (no of subjects)
| | | |
|
Mild intermittent
|
11
|
3
|
14
|
|
Mild persistent
|
6
|
11
|
17
|
|
Moderate or severe persistent
|
3
|
6
|
9
|
|
Asthma medication (no of subjects)
|
-
|
-
|
-
|
|
Oral salbutamol
|
10
|
13
|
23
|
|
Inhaled salbutamol
|
6
|
7
|
13
|
|
Oral theophylline
|
2
|
5
|
7
|
|
Oral steroids
|
2
|
6
|
8
|
|
Inhaled steroids
|
6
|
10
|
16
|
|
Spirometry results, mean ± SE
| | | |
|
FVC (L)
|
3.3 ± 0.1
|
3.1 ± 0.1
|
3.2 ± 0.1
|
|
FEV1 (L)
|
2.7 ± 0.1
|
2.6 ± 0.1
|
2.7 ± 0.1
|
|
PEFR (L)
|
4.3 ± 0.2
|
4.1 ± 0.2
|
4.2 ± 0.1
|
|
Autonomic function testing results
| |
1.1 ± 0.03
|
1.2 ± 0.02
|
|
HR ratio*
|
1.21 ± 0.04
|
1.1 ± 0.03
|
1.2 ± 0.02
|
|
HR difference
|
23.1 ± 1.8
|
23.1 ± 1.5
|
23.01 ± 1.2
|
|
Valsalva ratio
|
1.3 ± 0.1
|
1.2 ± 0.05
|
1.2 ± 0.04
|
